<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Lapatinib_Untruths_You%27ve_Been_Compelled_About</id>
		<title>Lapatinib Untruths You've Been Compelled About - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=Lapatinib_Untruths_You%27ve_Been_Compelled_About"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Lapatinib_Untruths_You%27ve_Been_Compelled_About&amp;action=history"/>
		<updated>2026-05-03T16:16:56Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=Lapatinib_Untruths_You%27ve_Been_Compelled_About&amp;diff=197909&amp;oldid=prev</id>
		<title>Salebabies1: Створена сторінка: 8.0 statistical software. 2.9. Ethics The study was approved by the Institutional Review Board of the Mexican Institute for Social Security (IMSS) of the partic...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=Lapatinib_Untruths_You%27ve_Been_Compelled_About&amp;diff=197909&amp;oldid=prev"/>
				<updated>2017-07-05T02:03:41Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: 8.0 statistical software. 2.9. Ethics The study was approved by the Institutional Review Board of the Mexican Institute for Social Security (IMSS) of the partic...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;8.0 statistical software. 2.9. Ethics The study was approved by the Institutional Review Board of the Mexican Institute for Social Security (IMSS) of the participating hospital (approval number IMSS R-2010-1303-29), [http://www.selleck.co.jp/products/pembrolizumab.html anti-PD-1 monoclonal antibody] with all subjects providing written informed consent. 3. Results Figure 1 presents the study's flow chart of the patients meeting the inclusion criteria. Of 54 RA patients with a suspicion of ILD, 15 were excluded from the study because they declined to participate (n = 5) or had exclusion criteria for the study (n = 10), whereas, of 59 RA patients without ILD, 17 were excluded because they met one of the exclusion criteria (see Figure 1). Figure 1 Study flow chart. RA: rheumatoid arthritis; RA-ILD: rheumatoid arthritis with interstitial lung disease; PFT: pulmonary function tests; HRCT: high-resolution computed tomography; FVC: forced vital capacity; anti-CCP: anti-cyclic citrullinated peptide ... Table 1 compares the characteristics of patients with RA-ILD (n = 39) versus RA only (n = 42). Patients with RA-ILD had higher scores for DAS28 (3.9 versus 2.5, P [http://www.selleckchem.com/products/crenolanib-cp-868596.html Crenolanib ic50] and HAQ-Di (0.8 versus 0.4, P [http://www.selleckchem.com/products/Lapatinib-Ditosylate.html Selleck Lapatinib] disease (RA-ILD) and patients with RA without interstitial lung disease (RA only). Figure 2 illustrates a comparison between anti-CCP2 titers in patients with RA only, compared with RA-ILD. Higher anti-CCP2 titers were observed in RA-ILD (77.9 versus 30.2, P&lt;/div&gt;</summary>
		<author><name>Salebabies1</name></author>	</entry>

	</feed>